Furthermore, dysregulation of the MET tyrosine kinase is associated with resistance to targeted therapies in cancer patients and frequently occurs in non-small cell lung cancer (NSCLC) patients with EGFR inhibitor resistance. This evidence concerns the gene EGFR and non-small cell lung carcinoma.